BDBM148355 US10017516, Compound 26::US9682983, 26
SMILES CC(=O)Nc1ccc2c(ccnc2c1)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1
InChI Key InChIKey=ZVCRZGKDKFWDKW-UHFFFAOYSA-N
Data 10 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 10 hits for monomerid = 148355
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 1.34E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 105nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 2.96E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
Affinity DataIC50: 8.10E+4nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 1.05E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase receptor R3(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 1.34E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 105nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1A(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 2.96E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
Affinity DataIC50: 8.10E+4nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ...More data for this Ligand-Target Pair
TargetBone morphogenetic protein receptor type-1B(Homo sapiens (Human))
The Brigham And Women'S Hospital
US Patent
The Brigham And Women'S Hospital
US Patent
Affinity DataIC50: 1.05E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2...More data for this Ligand-Target Pair